Ocular Physiology Clinical Trial
Official title:
Evaluating Quality of Life Benefits of ACUVUE® Theravision® With Ketotifen in Subjects With Ocular Allergies
NCT number | NCT05530889 |
Other study ID # | CR-6494 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | January 15, 2024 |
Est. completion date | May 13, 2024 |
Verified date | January 2024 |
Source | Johnson & Johnson Vision Care, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This will be a prospective, randomized, bilateral eye, crossover, non-masked single site pilot study to compare the severity of symptoms of itching between test and control lens after two weeks of wear.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | May 13, 2024 |
Est. primary completion date | May 13, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Potential participants must satisfy all of the following criteria to be enrolled in the study 1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. 2. Appear able and willing to adhere to the instructions set forth in this clinical protocol. 3. Be at least 18 years of age at the time of screening. 4. By self-report, habitually wear soft, daily, spherical contact lenses in both eyes. Habitual wear is defined as a minimum of 6 hours of wear per day, for a minimum of 5 days per week during the last 4 weeks. 5. Willing to wear study lenses for at least 5 days per week and 6 hours per day. 6. Possess a wearable pair of spectacles that provide correction for distance vision and agree to wear them on the day of the dispense visit (V2). 7. Must agree and be willing to not wear their habitual contact lenses on the day of the lens dispense visit (V2) 8. Report symptoms of allergy, including itchy eyes. 9. Oral medication and/or eye drops to treat allergy symptoms must have been used for at least 2 weeks, for a minimum of 3 times per week, prior to the screening visit. 10. Must be willing to cease use of habitual eye drops to relieve allergy symptoms during the ACUVUE® Theravision® with Ketotifen wear period. 11. The spherical equivalent of the participant's vertex corrected distance refraction must be between -0.50 and -7.00 DS (inclusive) in each eye. 12. The magnitude of the cylindrical component of the participant's vertex-corrected distance refraction must be no more than -1.00 DC (inclusive) in each eye. 13. Must achieve best corrected visual acuity (BCVA) of at least +0.20 logMAR in each eye. Exclusion Criteria: Potential participants who meet any of the following criteria will be excluded from participating in the study: 1. Be currently using any ocular medications, with the exception of eye drops for the treatment of their allergy symptoms. 2. Take any medications for which a stable regimen has not been achieved (i.e. have started a new medication or changed dosage of an existing medication within the last four weeks). 3. Have a known hypersensitivity or allergic reaction to ketotifen or sodium fluorescein. 4. Have participated in a contact lens or lens care product clinical trial within 14 days prior to study enrollment. 5. Be an employee (e.g., Investigator, Coordinator, Technician) of the Centre for Ocular Research & Education listed on the study Delegation Log or immediate family member of these employees (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse). 6. Have had or have planned (within the study period) any ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, iridotomy, retinal laser photocoagulation, etc.). 7. Be currently using bifocal, multifocal or monovision contact lenses, or wear lenses in an extended wear modality (sleep in lenses) 8. Have any active ocular infection of any type. 9. Have clinically significant (grade 3 or 4) corneal edema, corneal vascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear. 10. Have clinically significant (grade 3 or 4) papillary conjunctivitis or bulbar injection which might interfere with contact lens wear and that are unlikely to be related to their ocular allergy (at the investigator's discretion). 11. Have fluctuations in vision due to clinically significant dry eye or other ocular conditions. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Johnson & Johnson Vision Care, Inc. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Subjective rating of itchiness | The severity of symptoms of itching will be compared (0-4 itching scale with 0.5 steps) between the test and control lens after 2 weeks of wear. | up to 2-week follow-up | |
Secondary | Subjective rating of comfort | Subjective ratings of comfort will be assessed on a 0 to 100 scale after each 2-week wear period. | up to 2-week follow-up | |
Secondary | Subjective rating of dryness | Subjective ratings of dryness will be assessed on a 0 to 100 scale after each 2-week wear period. | up to 2-week follow-up | |
Secondary | Subjective rating of vision | Subjective ratings of vision will be assessed on a 0 to 100 scale after each 2-week wear period. | up to 2-week follow-up | |
Secondary | Subjective rating of handling | Subjective ratings of handling will be assessed on a 0 to 100 scale after each 2-week wear period. | up to 2-week follow-up | |
Secondary | CLDEQ-8 Questionnaire | CLDEQ-8 is a dry eye questionnaire that asks the participant to reflect and rate their symptoms of eye discomfort and dryness over the past two weeks. A higher composite score indicates more severe dryness and the range is 0-37. | up to 2-week follow-up | |
Secondary | Comfortable and total CL wear time | Total wearing time and total comfortable wearing time will be recorded after each 2-week wear period. | up to 2-week follow-up | |
Secondary | Subject Preference Questionnaire | The subject will select their preferred study lens, test lens or control lens. | at the 2-week follow-up | |
Secondary | MiniRQLQ Questionnaire | The MiniRQLQ is a validated questionnaire that focuses on the impact of allergies on quality of life (QoL). It includes 14 questionnaire items in five sections (activities, practical problems, nasal symptoms, ocular symptoms, general symptoms) that address how allergies impacted QoL during the previous week, by asking the user to rate how troubling each item in the questionnaire was perceived. | up to 2-week follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00431392 -
Mechanisms of Choroidal Blood Flow Changes During Dark/Light Transitions
|
Phase 2 | |
Completed |
NCT06161012 -
Evaluation of Delefilcon A and Senofilcon A Daily Disposable Toric Soft Contact Lenses Over Two Weeks of Wear
|
N/A | |
Terminated |
NCT00708357 -
Does eNOS Gene Polymorphism Play a Role in the Maintenance of Basal Vascular Tone in the Choroid or Optic Nerve Head?
|
Phase 0 | |
Completed |
NCT05291936 -
Clinical Evaluation of Two Daily Disposable Toric Soft Contact Lenses Over One Week of Wear
|
N/A | |
Withdrawn |
NCT00712777 -
Relation Between Intraocular Pressure Lowering Effects of Topical Brimonidine and Alpha 2 Receptor Polymorphism
|
N/A | |
Completed |
NCT00709423 -
Effects of Moxaverine and Placebo on Ocular Blood Flow
|
Phase 2 | |
Completed |
NCT00708929 -
Does Complement Factor H Gene Polymorphism Play a Role in the Regulation of Vascular Tone in the Choroid?
|
N/A | |
Completed |
NCT00712400 -
Effects of Latanoprost on Choroidal Blood Flow Regulation in Human Subjects
|
N/A | |
Completed |
NCT01663688 -
Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for 3D Measurements of the Eye
|
N/A | |
Completed |
NCT05427539 -
Feasibility Evaluation of Daily Disposable Toric Soft Contact Lenses Manufactured With an Alternative Hydration Process
|
N/A | |
Completed |
NCT05713552 -
Evaluation of ACUVUE® OASYS 1-Day for Astigmatism Contact Lenses With Alternative Lidstock
|
N/A | |
Withdrawn |
NCT00406731 -
Role of Endothelin- and Nitric Oxide-system in the Regulation of Optic Nerve Head Blood Flow During Changes in Ocular Perfusion Pressure
|
Phase 2 | |
Completed |
NCT00706927 -
Effect of Xalacom® (Latanoprost/Timolol) and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
|
N/A | |
Completed |
NCT00275730 -
Effects of Indomethacin on Retinal and Choroidal Blood Flow in Healthy Volunteers
|
N/A | |
Completed |
NCT00712764 -
Role of Adenosine in the Control of Choroidal Blood Flow During Changes in Ocular Perfusion Pressure.
|
N/A | |
Completed |
NCT00312416 -
Effects of Topical Clonidine vs. Brimonidine on Choroidal Blood Flow and Intraocular Pressure During Isometric Exercise
|
Phase 4 | |
Completed |
NCT00712907 -
Effects of Vitamin C on Hyperoxia-Induced Reduction of Retinal Blood Flow
|
N/A | |
Completed |
NCT00431730 -
Is There a Difference in Flicker Induced Vasodilatation Between Smokers and Non-Smokers?
|
N/A | |
Withdrawn |
NCT00991900 -
Short Term and Day to Day Reproducibility of Reflectometric Measurement of Retinal Oxygen Saturation in Healthy Subjects
|
||
Completed |
NCT00280462 -
Choroidal Blood Flow Regulation During Isometric Exercise: Effects of Ca2+-Channel Blockade
|
N/A |